Ailanthone: A novel potential drug for treating human cancer (Review)
| Autor: | Kaijun Gao, Chen Hang, Haixiang Ding, Xifeng Lao, Zhilong Yan, Yangtao Jia, Xiuchong Yu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Oncogene business.industry Myeloid leukemia Cancer Drug resistance medicine.disease Molecular medicine 03 medical and health sciences Prostate cancer chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Oncology chemistry 030220 oncology & carcinogenesis Cancer cell medicine Cancer research Ailanthone business |
| Zdroj: | Oncology Letters. 20:1489-1503 |
| ISSN: | 1792-1082 1792-1074 |
| Popis: | Cancer is the second leading cause of death after cardiovascular disease. In 2015, >8.7 million people died worldwide due to cancer, and by 2030 this figure is expected to increase to ~13.1 million. Tumor chemotherapy drugs have specific toxicity and side effects, and patients can also develop secondary drug resistance. To prevent and treat cancer, scientists have developed novel drugs with improved antitumor effects and decreased toxicity. Ailanthone (AIL) is a quassinoid extract from the traditional Chinese medicine plant Ailanthus altissima, which is known to have anti-inflammatory and antimalarial effects. An increasing number of studies have focused on AIL due to its antitumor activity. AIL can inhibit cell proliferation and induce apoptosis by up- or downregulating cancer-associated molecules, which ultimately leads to cancer cell death. Antitumor effects of AIL have been observed in melanoma, acute myeloid leukemia, bladder, lung, breast, gastric and prostate cancer and vestibular neurilemmoma. To the best of our knowledge, the present study is the first review to describe the antitumor mechanisms of AIL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |